Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.
Although if approved, it’s not likely to launch in the U.S. for quite some time.
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium’s Xtampza over Purdue’s OxyContin
FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer’s drug; GSK Q3 sales driven by HIV, respiratory drugs
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
Pfizer sues J&J over Remicade contracts; drugmakers trim sales forces for rare-disease drugs; Roche’s oncology business under siege from biosimilars
Get the most out of
Register for free and enjoy unlimited access to: